Global economic slowdown and uncertainty driven by the Middle East conflict could potentially increase operational costs for ADMA Biologics through higher energy and transportation expenses, and may impact overall healthcare spending budgets, although demand for essential biologics might be relatively inelastic.

A strong US job market with low unemployment (4.3% in March) supports a healthy domestic economy, which is positive for healthcare demand in ADMA's primary market, the United States. This could also influence labor costs for the company's operations.

The ongoing investigations into ADMA Biologics regarding alleged securities fraud and a short-seller report suggesting improper channel stuffing have introduced significant company-specific risk and volatility, impacting investor sentiment and the stock price, independent of broader market conditions.